NorthWest Biotherapeutics Inc (NWBO)

[sharpie510]

If they can separate out the RCT data based on IDH status, they will have completely different survival curves for IDH mutant and IDH wild-type. IDH wild-type do very poorly under standard of care. Virtually ALL the long term survivors under SOC are IDH mutant and are now determined to be NOT TRUE PRIMARY GLIOBLASTOMA. But even if they don't have IDH status in the RCT data, the RAs certainly know it is the IDH mutant patients that were inflating the SOC survival curve. This will work in NWBOs favor.

Every patient in the long term cohort that Dr. Liau is speaking of here are mesenchymal. Mesenchymal is predominantly IDH wild-type. She says she has a couple dozen of these survivors OUTSIDE of the phase 3 trial at the 5:50 mark in the youtube video above. To reiterate, ALL of these are mesenchymal.

At the 7:47 mark, you can see the chart that there are virtually ZERO mesenchymal that live beyond 5 years under SOC. She states it is the proneural group that typically does well under SOC, and they are now not considered primary glioblastoma. The survival curve will be shifted UP and to the RIGHT for pGBM patients that are fortunate enough to get DCVax-L.

I'm looking forward to the unblinded phase 3 top line results. This new WHO definition for glioblastoma makes me feel even more confident that the trial results when finally published will be groundbreaking and extremely positive. I'm happy for patients, and happy for all the long NWBO investors that have helped to keep this company afloat.